-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|August 20, 2007

Latebreakers: First-in-class CCR5 inhibitor OK'd

Maraviroc (Selzentry, Pfizer), the first CCR5 inhibitor, was recently approved following priority review by the FDA.


Latest CME